Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1996 Apr;60(4):359–361. doi: 10.1136/jnnp.60.4.359

Intravenous immunoglobulin treatment in neurological diseases.

A Otten, M Vermeulen, P M Bossuyt, A Otten
PMCID: PMC1073883  PMID: 8774395

Full text

PDF
359

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amato A. A., Barohn R. J., Jackson C. E., Pappert E. J., Sahenk Z., Kissel J. T. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology. 1994 Aug;44(8):1516–1518. doi: 10.1212/wnl.44.8.1516. [DOI] [PubMed] [Google Scholar]
  2. Appleton R. E. The role of vigabatrin in the management of infantile epileptic syndromes. Neurology. 1993 Nov;43(11 Suppl 5):S21–S23. [PubMed] [Google Scholar]
  3. Azulay J. P., Blin O., Pouget J., Boucraut J., Billé-Turc F., Carles G., Serratrice G. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994 Mar;44(3 Pt 1):429–432. doi: 10.1212/wnl.44.3_part_1.429. [DOI] [PubMed] [Google Scholar]
  4. Cherin P., Herson S., Wechsler B., Piette J. C., Bletry O., Coutellier A., Ziza J. M., Godeau P. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991 Aug;91(2):162–168. doi: 10.1016/0002-9343(91)90009-m. [DOI] [PubMed] [Google Scholar]
  5. Cherin P., Piette J. C., Wechsler B., Bletry O., Ziza J. M., Laraki R., Godeau P., Herson S. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994 Jun;21(6):1092–1097. [PubMed] [Google Scholar]
  6. Connelly J. F. Vigabatrin. Ann Pharmacother. 1993 Feb;27(2):197–204. doi: 10.1177/106002809302700215. [DOI] [PubMed] [Google Scholar]
  7. Cornelio F., Antozzi C., Mantegazza R., Confalonieri P., Berta E., Peluchetti D., Sghirlanzoni A., Fiacchino F. Immunosuppressive treatments. Their efficacy on myasthenia gravis patients' outcome and on the natural course of the disease. Ann N Y Acad Sci. 1993 Jun 21;681:594–602. doi: 10.1111/j.1749-6632.1993.tb22951.x. [DOI] [PubMed] [Google Scholar]
  8. Dalakas M. C. Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies. Clin Neuropharmacol. 1992 Oct;15(5):327–351. doi: 10.1097/00002826-199210000-00001. [DOI] [PubMed] [Google Scholar]
  9. Dalakas M. C., Illa I., Dambrosia J. M., Soueidan S. A., Stein D. P., Otero C., Dinsmore S. T., McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993 Dec 30;329(27):1993–2000. doi: 10.1056/NEJM199312303292704. [DOI] [PubMed] [Google Scholar]
  10. Dalakas M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991 Nov 21;325(21):1487–1498. doi: 10.1056/NEJM199111213252107. [DOI] [PubMed] [Google Scholar]
  11. Dyck P. J., Daube J., O'Brien P., Pineda A., Low P. A., Windebank A. J., Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986 Feb 20;314(8):461–465. doi: 10.1056/NEJM198602203140801. [DOI] [PubMed] [Google Scholar]
  12. Dyck P. J., Litchy W. J., Kratz K. M., Suarez G. A., Low P. A., Pineda A. A., Windebank A. J., Karnes J. L., O'Brien P. C. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994 Dec;36(6):838–845. doi: 10.1002/ana.410360607. [DOI] [PubMed] [Google Scholar]
  13. Dyck P. J., O'Brien P. C., Oviatt K. F., Dinapoli R. P., Daube J. R., Bartleson J. D., Mokri B., Swift T., Low P. A., Windebank A. J. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982 Feb;11(2):136–141. doi: 10.1002/ana.410110205. [DOI] [PubMed] [Google Scholar]
  14. Elliott J. L., Pestronk A. Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin. Neurology. 1994 May;44(5):967–968. doi: 10.1212/wnl.44.5.967. [DOI] [PubMed] [Google Scholar]
  15. Fanaroff A. A., Korones S. B., Wright L. L., Wright E. C., Poland R. L., Bauer C. B., Tyson J. E., Philips J. B., 3rd, Edwards W., Lucey J. F. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 1994 Apr 21;330(16):1107–1113. doi: 10.1056/NEJM199404213301602. [DOI] [PubMed] [Google Scholar]
  16. Feldman E. L., Bromberg M. B., Albers J. W., Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991 Sep;30(3):397–401. doi: 10.1002/ana.410300312. [DOI] [PubMed] [Google Scholar]
  17. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol. 1994 Jul;97 (Suppl 1):49–51. [PMC free article] [PubMed] [Google Scholar]
  18. Greenwood R. J., Newsom-Davis J., Hughes R. A., Aslan S., Bowden A. N., Chadwick D. W., Gordon N. S., McLellan D. L., Millac P., Stott R. B. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984 Apr 21;1(8382):877–879. doi: 10.1016/s0140-6736(84)91341-2. [DOI] [PubMed] [Google Scholar]
  19. Gross-Tsur V., Shalev R. S., Kazir E., Engelhard D., Amir N. Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand. 1993 Sep;88(3):204–209. doi: 10.1111/j.1600-0404.1993.tb04217.x. [DOI] [PubMed] [Google Scholar]
  20. Illum N., Taudorf K., Heilmann C., Smith T., Wulff K., Mansa B., Platz P. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics. 1990 May;21(2):87–90. doi: 10.1055/s-2008-1071468. [DOI] [PubMed] [Google Scholar]
  21. Jann S., Beretta S., Moggio M., Adobbati L., Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry. 1992 Jan;55(1):60–62. doi: 10.1136/jnnp.55.1.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Keller T., McGrath K., Newland A., Gatenby P., Cobcroft R., Gibson J. Indications for use of intravenous immunoglobulin. Recommendations of the Australasian Society of Blood Transfusion consensus symposium. Med J Aust. 1993 Aug 2;159(3):204–206. doi: 10.5694/j.1326-5377.1993.tb137790.x. [DOI] [PubMed] [Google Scholar]
  23. Miller F. W., Leitman S. F., Cronin M. E., Hicks J. E., Leff R. L., Wesley R., Fraser D. D., Dalakas M., Plotz P. H. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992 May 21;326(21):1380–1384. doi: 10.1056/NEJM199205213262102. [DOI] [PubMed] [Google Scholar]
  24. Molenaar D. S., de Haan R., Vermeulen M. Impairment, disability, or handicap in peripheral neuropathy: analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies. J Neurol Neurosurg Psychiatry. 1995 Aug;59(2):165–169. doi: 10.1136/jnnp.59.2.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Osterman P. O., Fagius J., Lundemo G., Pihlstedt P., Pirskanen R., Sidén A., Säfwenberg J. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984 Dec 8;2(8415):1296–1299. doi: 10.1016/s0140-6736(84)90819-5. [DOI] [PubMed] [Google Scholar]
  26. Pestronk A., Chaudhry V., Feldman E. L., Griffin J. W., Cornblath D. R., Denys E. H., Glasberg M., Kuncl R. W., Olney R. K., Yee W. C. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol. 1990 Mar;27(3):316–326. doi: 10.1002/ana.410270314. [DOI] [PubMed] [Google Scholar]
  27. Ratko T. A., Burnett D. A., Foulke G. E., Matuszewski K. A., Sacher R. A. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA. 1995 Jun 21;273(23):1865–1870. [PubMed] [Google Scholar]
  28. Ronda N., Hurez V., Kazatchkine M. D. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang. 1993;64(2):65–72. doi: 10.1111/j.1423-0410.1993.tb02521.x. [DOI] [PubMed] [Google Scholar]
  29. Schwartz S. A. Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes. Clin Rev Allergy. 1992 Spring-Summer;10(1-2):1–12. doi: 10.1007/978-1-4612-0417-6_1. [DOI] [PubMed] [Google Scholar]
  30. Soueidan S. A., Dalakas M. C. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin. Pediatr Res. 1993 Jan;33(1 Suppl):S95–100. doi: 10.1203/00006450-199333011-00017. [DOI] [PubMed] [Google Scholar]
  31. Soueidan S. A., Dalakas M. C. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993 May;43(5):876–879. doi: 10.1212/wnl.43.5.876. [DOI] [PubMed] [Google Scholar]
  32. Stricker R. B., Kwiatkowska B. J., Habis J. A., Kiprov D. D. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol. 1993 Aug;50(8):837–840. doi: 10.1001/archneur.1993.00540080046012. [DOI] [PubMed] [Google Scholar]
  33. Sullivan K. M., Kopecky K. J., Jocom J., Fisher L., Buckner C. D., Meyers J. D., Counts G. W., Bowden R. A., Peterson F. B., Witherspoon R. P. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990 Sep 13;323(11):705–712. doi: 10.1056/NEJM199009133231103. [DOI] [PubMed] [Google Scholar]
  34. Thornton C. A., Griggs R. C. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol. 1994 Mar;35(3):260–268. doi: 10.1002/ana.410350304. [DOI] [PubMed] [Google Scholar]
  35. Vermeulen M., van Doorn P. A., Brand A., Strengers P. F., Jennekens F. G., Busch H. F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):36–39. doi: 10.1136/jnnp.56.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. van Doorn P. A., Brand A., Strengers P. F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–212. doi: 10.1212/wnl.40.2.209. [DOI] [PubMed] [Google Scholar]
  37. van Rijckevorsel-Harmant K., Delire M., Schmitz-Moorman W., Wieser H. G. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res. 1994;24(3):162–166. doi: 10.1007/BF02592447. [DOI] [PubMed] [Google Scholar]
  38. van der Meché F. G., Schmitz P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992 Apr 23;326(17):1123–1129. doi: 10.1056/NEJM199204233261705. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES